The global demand for Retinal Biologics Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022-2028.
Retinal biologics are macromolecules like genetically engineered protein, peptides, and aptamers used as therapeutic agents to treat various ocular diseases. Ocular inflammation can occur in patients with inflammatory bowel disease (IBD), ankylosing spondylitis (AS), psoriasis, Bechet's disease (BD), juvenile idiopathic arthritis (JIA), and rheumatoid arthritis (RA). Biologics are delivered to the tissues at the back of the eyes for patients with recalcitrant diseases who are intolerant to immunosuppressive therapy or conventional immunomodulatory therapy. Retinal biologics has been extensively used in children with uveitis and treats age-related macular degeneration and other retinal vascular diseases.
Market Dynamics
The retinal biologics market is witnessing significant momentum in recent years due to the escalation of ophthalmic disorders worldwide. Growing instances of retinal conditions like macular degeneration related to age, infectious retinitis, macular edema, diabetic retinopathy, macular hole, retinoblastoma, retinal degeneration, uveitis, and retinoschisis leading to a permanent loss of vision will be the primary stimulant for the growth of this market. Consistent efforts in developing innovative treatment options, increased investments in the ophthalmology sector to raise awareness and diagnosis of different disorders related to the eye will be a market booster. The high treatment cost and limited long-term safety will hamper market growth since retinal biologics is not considered first-line therapy in most patients.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of retinal biologics.
Market Segmentation
This section of the retinal biologics market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Drug Class
- VEGF-A Antagonist
- TNF-a Inhibitor
By Disease Indication
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Retinal Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Retinal Biologics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the retinal biologics market include F. Hoffmann-La Roche Ltd,Regeneron Pharmaceuticals Inc.,AbbVie Inc.,MeiraGTx Limited,Oxurion NV,Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.